Periostin-binding DNA aptamer inhibits breast cancer growth and metastasis

Molecular Therapy

Volumn 21, Issue 5, 2013, Pages 1004-1013

  Lee, Yu Jin ^a,c   Kim, Il Shin ^a   Park, Soo Ah ^a   Kim, Youndong ^c   Lee, Jeung Eun ^a   Noh, Dong Young ^b   Kim, Kyong Tai ^c   Ryu, Sung Ho ^c   Suh, Pann Ghill ^a  

^a Ulsan National Institute of Science and Technology   (South Korea)

^b Seoul National University   (South Korea)

^c Pohang University of Science and Technology (POSTECH)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA5 INTEGRIN; APTAMER; TRANSCRIPTION FACTOR RUNX2; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BINDING AFFINITY; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL ADHESION; CELL INVASION; CELL MIGRATION; CONFERENCE PAPER; CONTROLLED STUDY; DISTANT METASTASIS; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SPECIFICITY; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SPLEEN METASTASIS;

EID: 84877079933     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.30     Document Type: Article

References (49)

1. Friedl, P and Wolf, K (2003). Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 3: 362-374.
2. Yokota, J (2000). Tumor progression and metastasis. Carcinogenesis 21: 497-503.
3. Jacks, T and Weinberg, RA (2002). Taking the study of cancer cell survival to a new dimension. Cell 111: 923-925.
4. Chambers, AF, Groom, AC and MacDonald, IC (2002). Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563-572.
5. Malanchi, I, Santamaria-Martez, A, Susanto, E, Peng, H, Lehr, HA, Delaloye, JF et al. (2012). Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481: 85-89.
6. Visvader, JE and Lindeman, GJ (2008). Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768.
7. Takeshita, S, Kikuno, R, Tezuka, K and Amann, E (1993). Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J 294 (Pt 1): 271-278.
8. Gillan, L, Matei, D, Fishman, DA, Gerbin, CS, Karlan, BY and Chang, DD (2002). Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res 62: 5358-5364.
9. Takeshita, S, Kikuno, R, Tezuka, K and Amann, E (1993). Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J 294 (Pt 1): 271-278.
10. Rios, H, Koushik, SV, Wang, H, Wang, J, Zhou, HM, Lindsley, A et al. (2005). periostin null mice exhibit dwarfism, incisor enamel defects, and an early-onset periodontal disease-like phenotype. Mol Cell Biol 25: 11131-11144.
11. Stanton, LW, Garrard, LJ, Damm, D, Garrick, BL, Lam, A, Kapoun, AM et al. (2000). Altered patterns of gene expression in response to myocardial infarction. Circ Res 86: 939-945.
12. Roy, S, Patel, D, Khanna, S, Gordillo, GM, Biswas, S, Friedman, A et al. (2007). Transcriptome-wide analysis of blood vessels laser captured from human skin and chronic wound-edge tissue. Proc Natl Acad Sci USA 104: 14472-14477.
13. Kruzynska-Frejtag, A, Wang, J, Maeda, M, Rogers, R, Krug, E, Hoffman, S et al. (2004). Periostin is expressed within the developing teeth at the sites of epithelialmesenchymal interaction. Dev Dyn 229: 857-868.
14. Kudo, Y, Siriwardena, BS, Hatano, H, Ogawa, I and Takata, T (2007). Periostin: novel diagnostic and therapeutic target for cancer. Histol Histopathol 22: 1167-1174.
15. Puglisi, F, Puppin, C, Pegolo, E, Andreetta, C, Pascoletti, G, D'Aurizio, F et al. (2008). Expression of periostin in human breast cancer. J Clin Pathol 61: 494-498.
16. Zhang, Y, Zhang, G, Li, J, Tao, Q and Tang, W (2010). The expression analysis of periostin in human breast cancer. J Surg Res 160: 102-106.
17. Conti S, Voorzanger-Rousselot, N, Litvin, J, Clardin, P and Garnero, P (2011). Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases. Int J Cancer 128: 352-360.
18. Sasaki, H, Yu, CY, Dai, M, Tam, C, Loda, M, Auclair, D et al. (2003). Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer. Breast Cancer Res Treat 77: 245-252.
19. Baril, P, Gangeswaran, R, Mahon, PC, Caulee, K, Kocher, HM, Harada, T et al. (2007). Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxiainduced cell death: role of the beta4 integrin and the PI3k pathway. Oncogene 26: 2082-2094.
20. Bao, S, Ouyang, G, Bai, X, Huang, Z, Ma, C, Liu, M et al. (2004). Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 5: 329-339.
21. Shao, R, Bao, S, Bai, X, Blanchette, C, Anderson, RM, Dang, T et al. (2004). Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol Cell Biol 24: 3992-4003.
22. Sawyers, C (2004). Targeted cancer therapy. Nature 432: 294-297.
23. Zangemeister-Wittke, U (2005). Antibodies for targeted cancer therapy-technical aspects and clinical perspectives. Pathobiology 72: 279-286.
24. Ireson, CR and Kelland, LR (2006). Discovery and development of anticancer aptamers. Mol Cancer Ther 5: 2957-2962.
25. Que-Gewirth, NS and Sullenger, BA (2007). Gene therapy progress and prospects: RNA aptamers. Gene Ther 14: 283-291.
26. Kaur, G and Roy, I (2008). Therapeutic applications of aptamers. Expert Opin Investig Drugs 17: 43-60.
27. Cerchia, L and de Franciscis, V (2007). Nucleic acid-based aptamers as promising therapeutics in neoplastic diseases. Methods Mol Biol 361: 187-200.
28. Cerchia, L and de Franciscis, V (2010). Targeting cancer cells with nucleic acid aptamers. Trends Biotechnol 28: 517-525.
29. Liu, Y, Kuan, CT, Mi, J, Zhang, X, Clary, BM, Bigner, DD et al. (2009). Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis. Biol Chem 390: 137-144.
30. Sako, Y, Minoghchi, S and Yanagida, T (2000). Single-molecule imaging of EGFR signalling on the surface of living cells. Nat Cell Biol 2: 168-172.
31. Mitra, SK and Schlaepfer, DD (2006). Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 18: 516-523.
32. Ouyang, G, Liu, M, Ruan, K, Song, G, Mao, Y and Bao, S (2009). Upregulated expression of periostin by hypoxia in non-small-cell lung cancer cells promotes cell survival via the Akt/PKB pathway. Cancer Lett 281: 213-219.
33. Siriwardena, BS, Kudo, Y, Ogawa, I, Kitagawa, M, Kitajima, S, Hatano, H et al. (2006). Periostin is frequently overexpressed and enhances invasion and angiogenesis in oral cancer. Br J Cancer 95: 1396-1403.
34. Hofmeister, V, Schrama, D and Becker, JC (2008). Anti-cancer therapies targeting the tumor stroma. Cancer Immunol Immunother 57: 1-17.
35. Malanchi, I, Santamaria-Martez, A, Susanto, E, Peng, H, Lehr, HA, Delaloye, JF et al. (2012). Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481: 85-89.
36. Kii, I, Nishiyama, T, Li, M, Matsumoto, K, Saito, M, Amizuka, N et al. (2010). Incorporation of tenascin-C into the extracellular matrix by periostin underlies an extracellular meshwork architecture. J Biol Chem 285: 2028-2039.
37. Zhu, M, Saxton, RE, Ramos, L, Chang, DD, Karlan, BY, Gasson, JC et al. (2011). Neutralizing monoclonal antibody to periostin inhibits ovarian tumor growth and metastasis. Mol Cancer Ther 10: 1500-1508.
38. Orecchia, P, Conte, R, Balza, E, Castellani, P, Borsi, L, Zardi, L et al. (2011). Identification of a novel cell binding site of periostin involved in tumour growth. Eur J Cancer 47: 2221-2229.
39. Adams, GP, Schier, R, McCall, AM, Simmons, HH, Horak, EM, Alpaugh, RK et al. (2001). High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 61: 4750-4755.
40. Graff, CP and Wittrup, KD (2003). Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res 63: 1288-1296.
41. Wong, TY, Liew, G and Mitchell, P (2007). Clinical update: new treatments for agerelated macular degeneration. Lancet 370: 204-206.
42. Daniels, DA, Chen, H, Hicke, BJ, Swiderek, KM and Gold, L (2003). A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci USA 100: 15416-15421.
43. Mi, Z, Guo, H, Russell, MB, Liu, Y, Sullenger, BA and Kuo, PC (2009). RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther 17: 153-161.
44. Gold, L, Ayers, D, Bertino, J, Bock, C, Bock, A, Brody, EN et al. (2010). Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS ONE 5: e15004.
45. Vaught, JD, Bock, C, Carter, J, Fitzwater, T, Otis, M, Schneider, D et al. (2010). Expanding the chemistry of DNA for in vitro selection. J Am Chem Soc 132: 4141-4151.
46. Dassie, JP, Liu, XY, Thomas, GS, Whitaker, RM, Thiel, KW, Stockdale, KR et al. (2009). Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 27: 839-849.
47. Dewey, TM, Mundt, AA, Crouch, GJ, Zyzniewski, MC and Eaton, BE (1995). New uridine derivatives for systematic evolution of RNA ligands by exponential enrichment. J Am Chem Soc 117: 8474-8475.
48. Davies, DR, Gelinas, AD, Zhang, C, Rohloff, JC, Carter, JD, O'Connell, D et al. (2012). Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets. Proc Natl Acad Sci USA 109: 19971-19976.
49. Zhu, M, Fejzo, MS, Anderson, L, Dering, J, Ginther, C, Ramos, L et al. (2010). Periostin promotes ovarian cancer angiogenesis and metastasis. Gynecol Oncol 119: 337-344.